Secondary patents create what's called a "patent thicket," a defensive strategy where later-filed patents on formulations, delivery methods, and specific uses extend the commercial exclusivity window far beyond the original molecule patent
Orforglipron showed higher rates of adverse side effects such as nausea, vomiting and other gastrointestinal issues compared with semaglutide
"Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare"
Despite some studies showing cases of cancer development, the numbers reported are as minimal as one case
Pull the plunger back to draw air equal to the volume you plan to withdraw
The authors conclude that these findings highlight the therapeutic potential of selectively targeting the GLP-1 receptorTRPM5 signalling axis, paving the way for next-generation incretin-based therapies for type 2 diabetes